FDA Warns of Confusion Between Brintellix, Brilinta

Share this content:
FDA Warns of Confusion Between Brintellix, Brilinta
FDA Warns of Confusion Between Brintellix, Brilinta

FRIDAY, July 31, 2015 (HealthDay News) -- Confusion between the names of the antidepressant Brintellix (vortioxetine) and the antiplatelet Brilinta (ticagrelor) has led to the wrong medication being prescribed or dispensed, the U.S. Food and Drug Administration says.

While none of the reports indicate that a patient has used the wrong medication, reports of prescribing and dispensing errors are still being received by the FDA.

Physicians can reduce the risk of name confusion by including the generic name of the medication on prescriptions in addition to the brand name, along with the indication for their use.

In a safety announcement, the FDA urges "patients and health care professionals to report name confusion and medication errors involving Brintellix and Brilinta to the FDA MedWatch program."

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

California Lawsuit Claims AbbVie Paid Doctors to Prescribe Humira

California Lawsuit Claims AbbVie Paid Doctors to Prescribe ...

Claims physicians prescribed Humira because of financial kickbacks, not as best drug for patient

Patient-Directed IV Remifentanil Cuts Epidural Conversions

Patient-Directed IV Remifentanil Cuts Epidural Conversions

Patient-controlled remifentanil reduces proportion of conversions versus intramuscular pethidine

Pediatricians Have Role in Supporting Transgender Youth

Pediatricians Have Role in Supporting Transgender Youth

Recommendations developed for comprehensive care for youth identifying as transgender, gender diverse

is free, fast, and customized just for you!




Already a member?

Sign In Now »